CN102600227A - Compound functional red rice capsule - Google Patents
Compound functional red rice capsule Download PDFInfo
- Publication number
- CN102600227A CN102600227A CN2012100547546A CN201210054754A CN102600227A CN 102600227 A CN102600227 A CN 102600227A CN 2012100547546 A CN2012100547546 A CN 2012100547546A CN 201210054754 A CN201210054754 A CN 201210054754A CN 102600227 A CN102600227 A CN 102600227A
- Authority
- CN
- China
- Prior art keywords
- powder
- functional
- functional monascus
- capsule
- monascus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound functional red rice capsule, which is prepared by compounding functional red rice powder, natto powder, a balsam pear extract and ginkgo leaf extract powder. Due to the adoption of the capsule, the defect of limitation on the hypolipemic effect of functional red rice powder can be overcome. The compound functional red rice capsule provided by the invention is particularly suitable for treating or assisting in treating hyperlipidemia, hyperglycemia and cardiovascular diseases caused by hyperlipidemia and atherosclerosis. Under general conditions, the capsule can be used for reducing blood fat to a normal range after being taken continuously for one month, can be used for effectively lowering blood sugar, and has a lasting curative effect.
Description
Technical field
A kind of Chinese medicine compound that the present invention relates to field of medicaments is controlled agent; More particularly; The present invention relates to a kind of capsule that forms by functional Monascus powder, natto powder, Fructus Momordicae charantiae extract and Folium Ginkgo extract powder compound recipe, be specially adapted to hyperlipidemia and the treatment or the auxiliary treatment of the cardiovascular and cerebrovascular vessel that cause by hyperlipidemia and atherosclerosis.
Background technology
Along with people's growth in the living standard, hyperlipemia are also more and more, and corresponding cardiovascular and cerebrovascular disease, Patients with Fatty Liver are also more and more, and that gives the people has healthyly brought serious harm.Hyperlipidemia is meant that cholesterol in serum (TC), triglyceride (TG) and/or low density lipoprotein, LDL (LDL) a kind of whole body lipid metabolism too high and/or that serum high-density LP (HDL) is low excessively is unusual.China normal person fasting plasma lipid normal value: cholesterol 2.82～5.17mmol/L, triglyceride 0.23～1.24mmol/L.
The lots of clinical epidemiologic data shows: total plasma cholesterol (or LDL-C) level raises and in atherosclerotic generation and evolution, plays an important role; Be the important risk factor of coronary heart disease, cerebral infarction, and with the crowd in evidence of coronary heart diseases and mortality rate be significant positive correlation.Therefore, actively treat hyperlipemia effectively, can greatly reduce coronary heart disease, atherosclerotic incidence rate, improve patient's existence quality of life, prolong patient's life.
In the prior art, the domestic and international market has had many lipid lowerers, and it is obvious that the ester effect falls in Western medicine, but side effect is bigger, and common Chinese patent medicine effect is not ideal mostly.Though functional Monascus powder for example of the prior art has the effect of obvious suppression cholesterol biosynthesis and blood fat reducing, result of use is limited separately.
Summary of the invention
In order to solve the above-mentioned technical problem that exists in the prior art, the present invention proposes a kind of with natural function property Hongqu powder (red colouring agent), natto lyophilized powder, Fructus Momordicae charantiae extract, Folium Ginkgo extract are the compound capsule that feedstock production obtains.Of the present inventionly fall that the ester gum capsule is specially adapted to hyperlipidemia and the treatment or the auxiliary treatment of the cardiovascular and cerebrovascular vessel that caused by hyperlipidemia and atherosclerosis.
In order to solve the problems of the technologies described above, the present invention has adopted following technical scheme:
A kind of compound red leaven capsule is processed by the following materials based on weight medicine: functional Monascus powder 100-220 part; Natto powder 10-100 part, Fructus Momordicae charantiae extract powder: 5-20 part; Ginkgo leaf extract powder 10-30 part.
Preferably, said functional Monascus powder is 135-160 part; Natto powder 50-75 part, Fructus Momordicae charantiae extract powder 10-15 part; Ginkgo leaf extract powder 15-25 part.
Preferably, said functional Monascus powder is 150 parts; 60 parts of natto powders, 15 parts in Fructus Momordicae charantiae extract powder; 25 parts of ginkgo leaf extract powders.
Preferably, the crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 100-220mg wherein; Natto powder 10-100mg, Fructus Momordicae charantiae extract: 5-20mg; Folium Ginkgo extract 10-30mg.
Preferably, the crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 150mg wherein; Natto powder 60mg, Fructus Momordicae charantiae extract: 15mg; Folium Ginkgo extract 25mg.
Preferably, described functional Monascus powder is a water-soluble functional red koji powder.
Functional Monascus powder described in the present invention is meant the Hongqu powder (red colouring agent) that contains functional components Mo Nakelin K (Monacolin K) that utilizes the Monascus anka Nakazawa et sato fermenting and producing.The method for preparing of multiple functional Monascus powder and the cultural method for preparing the required Monascus anka Nakazawa et sato of functional Monascus have been arranged in the prior art.For example, a kind of method for preparing water-soluble functional red koji powder is disclosed in the Chinese invention patent application 200810234815.0; A kind of functional monoscaceae quick solid culture method is disclosed in the Chinese invention patent application 03139773.5.Above-mentioned patent documentation is quoted in presents as a reference.
Natto powder described in the present invention is meant the product that the Semen sojae atricolor that utilizes Bacillus natto inoculation steaming and decocting obtains at the proper temperature bottom fermentation.Japan must find to exist and the similar enzyme of thrombus dissolving enzyme in the natto by Jian Shi in 1987, and called after nattokinase (Nattokinase).Disclose the multiple method for preparing natto powder in the prior art, for example Japan Patent open source literature JP6261744A discloses a kind of method that adopts Chinese soybean to carry out solid fermentation production natto powder; One Chinese patent application 00107589.6 discloses a kind of production method of nattokinase.Nattokinase is an effective ingredient main in the natto powder; It has very strong fibrinolytic, can reduce the erythrocyte polymer, reduces the blood viscosity shearing stress; The inside and outside thrombosis of remarkable dissolve body; Obviously shorten the dissolution time of euglobulin and can activate venous endothelial cell producing plasminogen activator, fibrinolytic can keep in blood more than the 3h, reduces blood cholesterol levels and blood pressure.Compare with other thrombolytic class medicines, nattokinase has advantages such as safety is good, cost is low, fibrinolytic is strong, orally-ingestible, long action time.
Fructus Momordicae charantiae extract described in the present invention is meant that utilization is the Fructus Momordicae charantiae extract powder that momordica saponins, micromolecule polypeptide and active polysaccharide are main component that contains of raw material extraction with the fruit of cucurbitaceous plant Fructus Momordicae charantiae.Disclose the multiple method for preparing natto powder in the prior art, for example one Chinese patent application 200910000935.9 discloses a kind of method for preparing of Fructus Momordicae charantiae extract, and it can obtain the Fructus Momordicae charantiae extract pressed powder.Fructus Momordicae charantiae extract can promote absorption and the utilization to sugar in the blood of muscle cell and fatty tissue, and can strengthen the synthetic of glycogen in liver and the muscle.Can suppress sugar regeneration, thereby blood sugar lowering reduces glycosuria, and can prevent the acidosis that causes because of diabetes.All right activation of these article and repairing pancreas cell promote insulin secretion, improve the blood glucose utilization rate, and blood sugar content and prevent diabetes complication in the reduction blood are had remarkable result.
Semen Ginkgo extrac described in the present invention is meant and utilizes Folium Ginkgo through lixiviate, purification, extraction and the dry ginkgo leaf extract powder that obtains.In the Folium Ginkgo extract, ginkgetin is a main component, and it can protect capillary permeability, improves the cerebrovascular circulatory function, the protection brain cell, and coronary artery dilator recovers arteries elasticity, prevents thrombosis, the human body immunity improving ability.Ten minutes is useful per capita to coronary heart disease, angina pectoris, cerebral arteriosclerosis, alzheimer disease, hypertension, is described as " patron saint " of cardiovascular and cerebrovascular vessel.One Chinese patent application 02113684.X discloses a kind of process for preparing gingko leaf extract, and it is quoted in presents as a reference.
The dosage ratio of recipe ingredient of the present invention and each component is with each component modern pharmacology and clinical research in traditional experience and the prescription, particularly just confirms to obtain through the test of prescription repeatedly overall merit.
Another aspect of the present invention also relates to the capsular method for preparing of a kind of compound red leaven, comprises the preparation of crude drug, particulate preparation and processing step dry, encapsulated, control of product quality, it is characterized in that: according to functional Monascus powder 100-220 part; Natto powder 10-100 part, Fructus Momordicae charantiae extract powder: 5-20 part; Conduct preparation raw material after the prescription weighing of ginkgo leaf extract powder 10-30 part; Is that wetting agent is processed 40-200 purpose wet granular with above-mentioned powder with 95% ethanol, in 50-75 ℃ heated-air circulation oven, dries; Be lower than at relative humidity under 60% the operation workshop condition, filled capsules, the crude drug weight of filling in every capsules is 250mg; Adopt liquid chromatography technology, the capsular functional component of compound red leaven is carried out quantitative analysis, so that contain Mo Nakelin K 1-10mg, nattokinase 200-800FU, Charantin 1-5mg, ginkgetin 1-5mg in every capsules.
Preferably, the crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 150mg wherein; Natto powder 60mg, Fructus Momordicae charantiae extract: 15mg; Folium Ginkgo extract 25mg.
Preferably, described functional Monascus powder is a water-soluble functional red koji powder.
To compound red leaven capsule of the present invention sampling carrying out acute toxicity test, sample all greater than the 10000mg/Kg body weight, is nontoxic level material to the acute oral LD50 of the big white mice of male and female.
Compound red leaven capsule of the present invention, human body RD are 1000mg/60Kg every day.Show that through the functional evaluation experiment per os gave animal sample after 30 days, promptly had the effect of blood fat reducing and blood glucose, sample can suppress the rising of serum cholesterol and serum levels of triglyceride and the blood glucose of the high nutrient fodder rat of high fat.
After the clinical use of the compound red leaven capsule hundreds of examples of process of the present invention; Curative effect is reliable; Cooperate the light diet effective percentage to reach more than 90%, generally, take month later blood fat of capsule of the present invention continuously and just can be reduced in normal range; And effective blood sugar lowering, and has the persistent effect of curative effect.Compare with the medicine that the common lovastatin that adopts on the market is a primary raw material, capsule of the present invention does not increase liver, kidney burden, directly brings into play effect for reducing fat, and the liver protecting is suitable for taking for a long time.
The specific embodiment
Embodiment 1
The crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 100mg wherein; Natto powder 100mg, Fructus Momordicae charantiae extract: 20mg; Folium Ginkgo extract 30mg.Contain Mo Nakelin K 3mg in every capsules, nattokinase 800FU, Charantin 5mg, ginkgetin 5mg.
Embodiment 2
The crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 220mg wherein; Natto powder 10mg, Fructus Momordicae charantiae extract: 5mg; Folium Ginkgo extract 15mg.Contain Mo Nakelin K 10mg in every capsules, nattokinase 200FU, Charantin 1mg, ginkgetin 3mg.
Embodiment 3
The crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 150mg wherein; Natto powder 60mg, Fructus Momordicae charantiae extract: 15mg; Folium Ginkgo extract 25mg.Contain Mo Nakelin K 6mg in every capsules, nattokinase 500FU, Charantin 4mg, ginkgetin 4mg.
Embodiment 4
(1) case is selected
Select 15 routine hyperlipidemia and hyperglycemic patients, the age is 45-60 year, and wherein the male is 8 examples, and the women is 7 examples, and wherein the 1st group of 2 male 3 woman are numbered 1-5 and take embodiment 1 described capsule; The 2nd group of 3 male 2 woman are numbered 6-10 and take embodiment 2 described capsules; The 3rd group is 3 male 2 woman, is numbered 11-15 and takes embodiment 3 described capsules.
(2) administrated method
Everyone stops other fat-reducing medicaments during treating, take this capsule, 2 of every days, each one sooner or later.Be 30 days the course of treatment.
(3) observation item
Everyone take medicine morning the previous day with took medicine 30 days after second day morning carry out the inspection of 12 hours vein haemospasias of empty stomach, assay determination TC, TG, HDL, LDL.
(4) check result
Check result is as shown in table 1.
Claims (9)
1. a compound recipe functional Monascus capsule is processed by the following materials based on weight medicine: functional Monascus powder 100-220 part, natto powder 10-100 part, Fructus Momordicae charantiae extract powder 5-20 part, ginkgo leaf extract powder 10-30 part.
2. the described compound recipe functional Monascus of claim 1 capsule is characterized in that described functional Monascus powder is 135-160 part, and natto powder is 50-75 part, and the Fructus Momordicae charantiae extract powder is 10-15 part, and ginkgo leaf extract powder is 15-25 part.
3. the described compound recipe functional Monascus of claim 2 capsule is characterized in that said functional Monascus powder is 150 parts, and natto powder is 60 parts, and Fructus Momordicae charantiae extract is 15 parts, and Folium Ginkgo extract is 25 parts.
4. the described compound recipe functional Monascus of claim 1 capsule; It is characterized in that the crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 100-220mg wherein, natto powder 10-100mg; Fructus Momordicae charantiae extract powder 5-20mg, ginkgo leaf extract powder 10-30mg.
5. the described compound recipe functional Monascus of claim 3 capsule is characterized in that the crude drug weight of filling in every capsules is 250mg, and functional Monascus powder 150mg wherein, natto powder 60mg, Fructus Momordicae charantiae extract powder 15mg, ginkgo leaf extract powder 25mg.
6. each described compound recipe functional Monascus capsule of claim 1-5 is characterized in that described functional Monascus powder is a water-soluble functional red koji powder.
7. capsular method for preparing of compound recipe functional Monascus; Comprise the preparation of crude drug, particulate preparation and processing step dry, encapsulated, control of product quality; It is characterized in that: according to functional Monascus powder 100-220 part; Natto powder 10-100 part, Fructus Momordicae charantiae extract powder 5-20 part, conduct preparation raw material after the prescription weighing of ginkgo leaf extract powder 10-30 part; Is that wetting agent is processed 40-200 purpose wet granular with above-mentioned powder with 95% ethanol, in 50-75 ℃ heated-air circulation oven, dries; Be lower than at relative humidity under 60% the operation workshop condition, filled capsules, the crude drug weight of filling in every capsules is 250mg; Adopt liquid chromatography technology, the capsular functional component of compound red leaven is carried out quantitative analysis, so that contain Mo Nakelin K 1-10mg, nattokinase 200-800FU, Charantin 1-5mg, ginkgetin 1-5mg in every capsules.
8. the capsular method for preparing of the described compound recipe functional Monascus of claim 7 is characterized in that the crude drug weight of filling in every capsules is 250mg; And functional Monascus powder 150mg wherein; Natto powder 60mg; Fructus Momordicae charantiae extract powder 15mg; Ginkgo leaf extract powder 25mg.
9. claim 7 or the capsular method for preparing of 8 described compound recipe functional Monascus is characterized in that described functional Monascus powder is a water-soluble functional red koji powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100547546A CN102600227A (en) | 2012-03-05 | 2012-03-05 | Compound functional red rice capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100547546A CN102600227A (en) | 2012-03-05 | 2012-03-05 | Compound functional red rice capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102600227A true CN102600227A (en) | 2012-07-25 |
Family
ID=46518246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100547546A Pending CN102600227A (en) | 2012-03-05 | 2012-03-05 | Compound functional red rice capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600227A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
| CN103404757A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for hyperglycemia patients |
| CN104367624A (en) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | Compound preparation containing red yeast rice |
| CN104643070A (en) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | Formula of chitosan oligosaccharide and natto flour containing diet for patients suffering from cardiovascular and cerebrovascular diseases |
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN105533719A (en) * | 2016-01-29 | 2016-05-04 | 东莞市东卓中天生物科技有限公司 | Instant food for reducing blood fat and preparation method thereof |
| CN107198767A (en) * | 2017-05-19 | 2017-09-26 | 江苏江大五棵松生物科技有限公司 | It is a kind of to be used to prevent three high red yeast rice balsam pear complex peptides pieces |
| CN113559208A (en) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | A Chinese medicinal composition for protecting cardiovascular and cerebrovascular diseases, and its preparation method |
| CN114272223A (en) * | 2021-12-31 | 2022-04-05 | 江西樟树市正康医药生物科技有限公司 | Pseudo-ginseng red yeast rice ginkgo leaf capsule and production process thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308955A (en) * | 2000-12-20 | 2001-08-22 | 郭兴华 | Natural composition for preventing and treating cardiovascular and cerebrovascular diseases and its application |
| CN101637491A (en) * | 2009-06-10 | 2010-02-03 | 北京一品堂医药科技有限公司 | Health-care food having functions of assisting antidiabetics and assisting antiatheroscloresis preparation method thereof |
| CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
-
2012
- 2012-03-05 CN CN2012100547546A patent/CN102600227A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308955A (en) * | 2000-12-20 | 2001-08-22 | 郭兴华 | Natural composition for preventing and treating cardiovascular and cerebrovascular diseases and its application |
| CN101637491A (en) * | 2009-06-10 | 2010-02-03 | 北京一品堂医药科技有限公司 | Health-care food having functions of assisting antidiabetics and assisting antiatheroscloresis preparation method thereof |
| CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
| CN103404757A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for hyperglycemia patients |
| CN104367624A (en) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | Compound preparation containing red yeast rice |
| CN104643070A (en) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | Formula of chitosan oligosaccharide and natto flour containing diet for patients suffering from cardiovascular and cerebrovascular diseases |
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN105533719A (en) * | 2016-01-29 | 2016-05-04 | 东莞市东卓中天生物科技有限公司 | Instant food for reducing blood fat and preparation method thereof |
| CN107198767A (en) * | 2017-05-19 | 2017-09-26 | 江苏江大五棵松生物科技有限公司 | It is a kind of to be used to prevent three high red yeast rice balsam pear complex peptides pieces |
| CN113559208A (en) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | A Chinese medicinal composition for protecting cardiovascular and cerebrovascular diseases, and its preparation method |
| CN114272223A (en) * | 2021-12-31 | 2022-04-05 | 江西樟树市正康医药生物科技有限公司 | Pseudo-ginseng red yeast rice ginkgo leaf capsule and production process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600227A (en) | Compound functional red rice capsule | |
| CN102919836B (en) | Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof | |
| CN103385315B (en) | Vegetable oil composition with hypolipidemic effect as well as preparation method and application thereof | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN108392519A (en) | A kind of hypoglycemic composition and its preparation and application | |
| CN102488189B (en) | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof | |
| CN102125127A (en) | Functional highland barley red yeast rice tea and preparation method thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN105920439A (en) | Effective part composition containing corn stigma extract and preparation method and application of effective part composition | |
| CN102697843A (en) | Health care product for cleaning colon and promoting defecation, and eliminating toxin and beautifying skin and preparation method of same | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| Kuate et al. | The use of Cissus quadrangularis (CQR-300) in the management of components of metabolic syndrome in overweight and obese participants | |
| CN105168434B (en) | A kind of health care product and preparation method thereof of complementary reducing blood lipid | |
| CN107961293A (en) | A kind of sea-buckthorn tomato piece and preparation method thereof | |
| CN108041558A (en) | A kind of health soy sauce and preparation method thereof | |
| CN101336705B (en) | Health food and its preparation method | |
| CN102139057B (en) | Healthcare tea capable of lowering glucose | |
| CN101874818B (en) | Medicament or health-care product composition for reducing blood pressure or blood fat and preparation method and application thereof | |
| CN100364553C (en) | Natural medicinal composition for preparing diabete drug | |
| CN104273527B (en) | A kind of health composition and its production and use | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function | |
| CN105232802B (en) | Procyanidine composition with blood fat reducing effect and preparation method and application thereof | |
| CN104585767B (en) | A kind of health products and preparation technology for reducing blood fat | |
| CN104095868B (en) | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance | |
| CN106581142A (en) | Compound traditional Chinese medicine composition capable of regulating blood fat and purpose thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Wujiang Valley Biotechnology Co., Ltd. Jin Naichun Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wujiang Guli Biological Technology Co., Ltd. Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120725 |